Monitor HPV DNA in throat cancer to guide early response
Treatments studied
Part of Cancer clinical trials.
This study checks a substance called HPV DNA in your blood to see how your HPV-positive throat cancer responds early during treatment. It may help doctors spot who is responding well and who may need closer attention sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have throat cancer that is HPV-positive (the main tumor is HPV-positive)
- You are older than 18 years
- You can understand the study and sign the consent form
- You are planning treatment with the goal of cure (curative intent)
- The study team will check that your health and mental/addiction conditions won’t make it hard to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a blood test for HPV16 DNA can predict when HPV-related throat cancer comes back after treatment. It may help improve follow-up care by catching recurrence earlier.
This trial tests if monitoring cancer DNA left in your blood after surgery can help decide if you need additional treatment. It is for people with HPV-positive oropharynx (throat) cancer who have a certain amount of cancer DNA detected before surgery.
This observational study checks how well a blood test for HPV DNA (and other tumor genetic markers) predicts outcomes in certain throat cancers. It may help doctors better track the disease and plan treatment, because the trial validates these lab signals against real-world results.
This study looks at a blood test that finds DNA from HPV-related throat tumors. It may help doctors decide on surgery and check if the cancer is completely removed.
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Hear when a new Oropharynx Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.